Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial

[1]  W. Busse,et al.  Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial , 2016, The Lancet.

[2]  E. R. Sutherland,et al.  Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial , 2016, The Lancet.

[3]  Christopher E Brightling,et al.  Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies. , 2016, The Lancet. Respiratory medicine.

[4]  N. Kenyon,et al.  Benralizumab: a unique IL-5 inhibitor for severe asthma , 2016, Journal of asthma and allergy.

[5]  M. Larché,et al.  Treatment with anti‐cytokine monoclonal antibodies can potentiate the target cytokine rather than neutralize its activity , 2016, Allergy.

[6]  K. Ranade,et al.  Reductions in eosinophil biomarkers by benralizumab in patients with asthma. , 2016, Respiratory Medicine.

[7]  David Price,et al.  Predicting frequent asthma exacerbations using blood eosinophil count and other patient data routinely available in clinical practice , 2016, Journal of asthma and allergy.

[8]  L. Borish,et al.  The past, present, and future of monoclonal antibodies to IL-5 and eosinophilic asthma: a review , 2015, Journal of asthma and allergy.

[9]  E. Bateman,et al.  Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. , 2015, The Lancet. Respiratory medicine.

[10]  P. Paggiaro,et al.  Sputum eosinophilia is a determinant of FEV1 decline in occupational asthma: results of an observational study , 2015, BMJ Open.

[11]  M. Humbert,et al.  Asthma: still a promising future? , 2014, European Respiratory Review.

[12]  W. Busse,et al.  Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. , 2014, The Lancet. Respiratory medicine.

[13]  Ian D Pavord,et al.  Mepolizumab treatment in patients with severe eosinophilic asthma. , 2014, The New England journal of medicine.

[14]  Á. Cruz,et al.  Risk factors for death in patients with severe asthma* , 2014, Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia.

[15]  E. Bleecker,et al.  International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma , 2013, European Respiratory Journal.

[16]  Ian D Pavord,et al.  Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial , 2012, The Lancet.

[17]  Teresa To,et al.  Global asthma prevalence in adults: findings from the cross-sectional world health survey , 2012, BMC Public Health.

[18]  C. Mackay,et al.  MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function. , 2010, The Journal of allergy and clinical immunology.

[19]  W. Busse,et al.  Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor alpha antibody, in a phase I study of subjects with mild asthma. , 2010, The Journal of allergy and clinical immunology.

[20]  L. Lynd,et al.  Direct health care costs associated with asthma in British Columbia. , 2010, Canadian respiratory journal.

[21]  S. Wenzel,et al.  Tissue and BAL based biomarkers in asthma. , 2007, Immunology and allergy clinics of North America.

[22]  P. O'Byrne,et al.  Predictors of loss of asthma control induced by corticosteroid withdrawal. , 2006, Canadian respiratory journal.

[23]  J. Hankinson,et al.  General considerations for lung function testing , 2005, European Respiratory Journal.

[24]  Klas Svensson,et al.  Measurement properties and interpretation of three shortened versions of the asthma control questionnaire. , 2005, Respiratory medicine.

[25]  Romain A. Pauwels.  GLOBAL STRATEGY FOR ASTHMA MANAGEMENT AND PREVENTION , 1996 .

[26]  R. Silverman,et al.  A randomized trial of benralizumab, an antiinterleukin 5 receptor α monoclonal antibody, after acute asthma. , 2015, The American journal of emergency medicine.

[27]  M. Doyle-Waters,et al.  BMC Pulmonary Medicine BioMed Central Research article Economic burden of asthma: a systematic review , 2009 .